Trevi Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(c) Director and Officer Trading Arrangements
During the three months ended March 31, 2026, Thomas Sciascia, the Company's Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement for the sale of the Company's common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. This plan was adopted on January 21, 2026 and has an expiration date of December 31, 2026. Pursuant to the plan, the aggregate number of options to be exercised, and the aggregate number of shares of common stock to besold upon exercise of those options, is not to exceed 3,947.
None of our other directors or officers adopted orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during thethree months ended March 31, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.